We’re thrilled to announce a significant expansion into the Australian market through an exclusive manufacture and supply agreement with Breathe Life Sciences, a subsidiary of Bioxyne Limited.
This landmark partnership introduces the Curaleaf’s Que Medical Inhalation Device (QMID) to Australia, marking the entrance of the first certified liquid inhaler for cannabis-based medicines available on prescription.
Enhancing Patient Care and Access
The collaboration is set to make a real difference for patients. The QMID device is designed to deliver precise, consistent dosing and offers a simple, discreet way for patients to take their prescribed medication.
Sam Watson, CEO of Bioxyne Limited, commented on the importance of this step, stating, “This collaboration represents an important step in expanding access to regulated, medically compliant inhalation technology in Australia.”
A Growing Global Mission
The launch in Australia, a rapidly expanding market, is a key part of Curaleaf International’s broader strategy to deliver innovative medical technologies globally.
Juan Martinez, CEO of Curaleaf International, shared his enthusiasm: “We are excited to be partnering with Bioxyne and Breathe Life Sciences in Australia… The launch of the QMID in Australia is part of our wider mission to develop innovative medical technologies that support healthcare professionals in the delivery of treatment.”
Curaleaf International is committed to working with regulators and healthcare providers around the world to ensure patients have expanded access to safe, effective, and clinically integrated cannabis-based treatments.
QMID in Australia is part of Curaleaf International’s wider mission to develop innovative medical technologies that support healthcare professionals in the delivery of treatment.
The QMID is designed as a discreet and reliable inhalation device which, together with our partner Bioxyne, can now be offered to eligible patients in Australia”.
